Thomas J. Nevill

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn L. Slovak et al. · Blood · 2013 · 621 citations · Full text

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Oncology · 2015 · 354 citations

Unrelated Donors, Anti-thymocyte Globulin, Transplantation +9

Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.

Stephen H. Petersdorf, Kenneth J. Kopecky, Robert K. Stuart et al. · Blood · 2009 · 182 citations

Donor leukocyte infusions for multiple myeloma

Thomas J. Nevill, Deborah Marcellus, Pablo Parker et al. · Bone Marrow Transplantation · 2000 · 178 citations

Hematological Malignancy, Transplantation, Immunology +6

Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation

Thomas J. Nevill, Henry C. Fung, John D. Shepherd et al. · Blood · 1998 · 161 citations